EFICACIA DE LAS DROGAS ESTIMULANTES Y NO ESTIMULANTES PARA EL TRATAMIENTO DE LOS ADOLESCENTES CON TRASTORNO POR DEFICIT DE ATENCION E HIPERACTIVIDAD





EFICACIA DE LAS DROGAS ESTIMULANTES Y NO ESTIMULANTES PARA EL TRATAMIENTO DE LOS ADOLESCENTES CON TRASTORNO POR DEFICIT DE ATENCION E HIPERACTIVIDAD

(especial para SIIC © Derechos reservados)
Es probable que tanto los fármacos estimulantes como los no estimulantes sean tan efectivos para el tratamiento de los adolescentes con trastorno por déficit de atención e hiperactividad como lo son para los niños que sufren dicho trastorno, siempre que el cumplimiento terapéutico sea satisfactorio.
Autor:
Philip Hazell
Columnista Experto de SIIC

Institución:
University of Sydney


Artículos publicados por Philip Hazell
Recepción del artículo
24 de Abril, 2009
Aprobación
15 de Mayo, 2009
Primera edición
1 de Febrero, 2010
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El objetivo del presente artículo es brindar una actualización de una revisión selectiva publicada con anterioridad sobre la farmacología del trastorno por déficit de atención e hiperactividad (TDAH) en adolescentes. Cerca de la mitad de los niños con TDAH que reciben tratamiento farmacológico presentarán la afección durante la adolescencia, con una intensidad suficiente para requerir la continuidad del tratamiento. Asimismo, una proporción más pequeña de los individuos con TDAH pueden requerir el inicio del tratamiento durante la adolescencia. Las demandas académicas y sociales de la adolescencia pueden exacerbar el deterioro causado por los trastornos atencionales. Además, en comparación con los niños, los adolescentes realizan más actividades que requieren el empleo de sus habilidades atencionales durante la tarde y la noche. Es probable que los fármacos estimulantes y no estimulantes sean tan efectivos para el tratamiento de los adolescentes como lo son para el tratamiento de los niños, siempre que el cumplimiento terapéutico sea satisfactorio. Los fármacos de acción prolongada son preferidos frente a los de acción inmediata, ya que ofrecen un control sintomático superior a lo largo del día. Debe considerarse que los patrones de comorbilidad con TDAH cambian desde la infancia hasta la adolescencia y pueden requerir la modificación de la estrategia terapéutica. La elección del momento de interrupción del tratamiento debería ser conjunta entre el médico y el paciente. La inclusión del paciente en la decisión de interrumpir el tratamiento, seguida por una reevaluación, puede ser útil para evitar una interrupción prematura.

Palabras clave
trastorno por déficit de atención e hiperactividad, adolescencia, tratamiento farmacológico


Artículo completo

(castellano)
Extensión:  +/-12.57 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
The aim of the paper is to provide an update to a previously published selective review of the recent literature on the pharmacology of attention-deficit/hyperactivity disorder (ADHD) in adolescents. About one half of children medicated for ADHD will continue to experience sufficient impairment during adolescence to warrant the continuation of their treatment. A smaller number of people with ADHD may require treatment for the first time in adolescence. The academic and social demands of adolescence can exaggerate the impairment caused by attentional problems. Adolescents, more so than children, have activities in the afternoon and evening that will tax their attentional abilities. Stimulant and non-stimulant medications are likely to be as effective for adolescent patients as they are for younger children, provided treatment adherence is satisfactory. Long-acting medications are preferred over immediate release compounds as they provide better coverage of symptoms throughout the day. Patterns of comorbidity with ADHD change from childhood to adolescence and may require a shift in treatment strategy. Picking a time to discontinue treatment should be a decision shared by the clinician and the patient. A negotiated trial off treatment followed by a review can avert premature discontinuation of treatment.

Key words
attention deficit disorder with hyperactivity, adolescent, drug therapy


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Salud Mental
Relacionadas: Atención Primaria, Farmacología, Medicina Familiar, Medicina Farmacéutica, Neurología, Pediatría



Comprar este artículo
Extensión: 12.57 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Philip Hazell, Thomas Walker Hospital (Rivendell) Child, Adolescent and Family Mental Health Service , NSW 2138, Hospital Rd, Concord West, Australia
Bibliografía del artículo


1. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157:816-8, 2000.
2. Thomas CP, Conrad P, Casler R, Goodman E. Trends in the use of psychotropic medications among adolescents, 1994 to 2001. Psychiatr Serv 57:63-9, 2006.
3. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord 10:335-42, 2007.
4. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 42:24-31, 2008.
5. Upadhyaya HP, Rose K, Wang W, O'Rourke K, Sullivan B, Deas D, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 15:799-809, 2005.
6. Smith BH, Pelham WE, Jr., Gnagy E, Molina B, Evans S. The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for attention-deficit/hyperactivity disorder. J Consult Clin Psychol 68:489-99, 2000.
7. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 1475;165:1475-88.
8. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:266-79, 2006.
9. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82-90, 2006.
10. Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 17:235-9, 2004.
11. Greenhill LL, Findling RL, Swanson JM, ADHD SG. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39, 2002.
12. Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14:542-54, 2004.
13. Atomoxetine ADHD and Comorbid Major Depressive Disorder Study Group, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 17:407-20, 2007.
14. Wilens TE, Kratochvil C, Newcorn JH, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149-57, 2006.
15. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307-14, 2001.
16. Barrickman LL, Perry PJ, Allen AJ, Kuperman S, Arndt SV, Herrmann KJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 649-57, 1995.
17. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777-84, 1989.
18. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649-56, 2002.
19. Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 193-204, 2000.
20. Werry JS, Biederman J, Thisted R, Greenhill L, Ryan N. Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry 34:1239-45, 1995.
21. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol 17:334-47, 2007.
22. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:(Suppl 2) 26S-49S, 2002.
23. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adoles Psychiatry 13 (Suppl 1):7-30, 2004.
24. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43:559-67, 2004.
25. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159:572-8, 2005.
26. Findling RL, Short EJ, Manos MJ. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 40:1441-7, 2001.
27. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 165:553-5, 2008.
28. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 39:1095-116, 2004.
29. Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 15:751-63, 2005.
30. Wilens TE, Monuteaux MC, Snyder LE, Moore H, Whitley J, Gignac M. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? J Child Adolesc Psychopharmacol 15:787-98, 2005.
31. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M, et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 41:250-7, 2008.
32. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 82:149-58, 2004.
33. Henderson TA. Mania induction associated with atomoxetine. J Clin Psychopharmacol 24:567-8, 2004.
34. Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics 114:895-6, 2004.
35. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 15:996-1004, 2005.
36. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 162:58-64, 2005.
37. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol 13:123-36, 2003.
38. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 40:525-9, 2001.
39. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38:1047-50, 1999.
40. Hazell P. Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations. CNS Drugs 21:37-46, 2007.
41. Harpur RA, Thompson M, Daley D, Abikoff H, Sonuga-Barke EJS. The attention-deficit/hyperactivity disorder medication-related attitudes of patients and their parents. J Child Adolesc Psychopharmacol 18:461-73, 2008.
42. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10-41, 2007.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618